Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 3, Issue 3 , Pages 162-165 , July 2007

Commentary on “Health economics and the value of therapy in Alzheimer’s disease.” Report from the Alzheimer’s Association Research Roundtable on patient-reported outcomes and dementia research

  • Lori B. Frank

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: 301-654-9729; Fax: 301-654-9864.

References 

  1. Federal Register. Draft guidance for industry on patient-reported outcome measures (use in medical product development to support labeling claims). Fed Register. 2006;71:5862–5863(available at: http://www.fda.gov/cdrh/ggpmain.html)
  2. Food and Drug Administration. Available at: http://www.fda.gov/cvm/guidance/guidance.html. Accessed May 22, 2007.
  3. Willke RJ, Burke LB, Erickson P. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials. 2004;25:535–552
  4. DeBrota D, Demitrack M, Landin R, Kobak KA, Greist JH, Potter W. A comparison between interactive voice response system administered HAM-D and clinician-administered HAM-D in patients with major depressive episode. 1999;[abstract]. National Institute of Mental Health, New Clinical Drug Evaluation Unit. In: 39th annual meeting. Boca Raton, FL
  5. Teeter JG, Bleecker ER. Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest. 1998;113:272–277
  6. Post SG, Stucky JC, Whitehouse PJ, Ollerton S, Durki C, Robbins D, et al. A focus group on cognition-enhancing medication in Alzheimer’s disease: disparities between professionals and consumers. Alzheimer Dis Assoc Disord. 2001;15:80–88
  7. Wilson IB, Cleary PD. Linking clinical variables with health related quality of life (A conceptual model of patient outcomes). JAMA. 1995;273:59–65
  8. Clancy CM, Eisenberg JM. Outcomes research: measuring the end results of health care. Science. 1998;282:245–246
  9. Wennberg JE. Outcomes research, cost containment, and the fear of healthcare rationing. N Engl J Med. 1990;323:1202–1204
  10. Osoba D. HRQOL in oncology: “watching the ripples.”. ISOQOL Newslett. 2007;11:6–9
  11. Salive ME, Mayfield JA, Weissman NW. Patient outcomes research teams and the Agency for Health Care Policy and Research. Health Serv Res. 1990;25:697–708
  12. Ready RE. Commentary on “Health economics and the value of therapy in Alzheimer’s disease” (Patient-reported outcomes in clinical trials for Alzheimer’s disease). Alzheimers Dement. 2007;3:172–176
  13. Clegg A, Bryant J, Nicholson T, Gerrard K, McIntyre L, de Broe S, et al. Drugs for Alzheimer’s disease: HTA report; clinical and cost effectiveness of donepezil, rivastigmine and galantamine for Alzheimer’s disease. Available at: http://guidance.nice.org.uk/page.aspx?o14427 <http://guidance.nice.org.uk/page.aspx?o%0114427>. Accessed October 28, 2006.
  14. National Institute for Health and Clinical Excellence. Donepezil, rivastigmine, galantamine and memantine for the treatment of Alzheimer’s disease, appeal by Easai Limited (section 2.7). Available at. http://guidance.nice.org.uk/page.aspx?o=371762. Accessed April 18, 2007.
  15. Rockwood K, Black SE, Robillard A, Lussier I. Potential treatment effects of donepezil not detected in Alzheimer’s disease clinical trials: a physician survey. Int J Geriatr Psychiatry. 2004;19:954–960

PII: S1552-5260(07)00478-5

doi: 10.1016/j.jalz.2007.04.383

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 3, Issue 3 , Pages 162-165 , July 2007

Article Tools

* Image Usage & Resolution